If Aldous Huxley had been born in Palo Alto, he might have traded his mescaline for machine learning. Instead of The Doors of Perception, perhaps we’d have The Algorithms of Awareness. That, in essence, is the dream animating Mindstate Design Labs — a Silicon Valley startup determined to engineer enlightenment without the mess of actually feeling it.
They call it “the least psychedelic psychedelic that’s psychoactive.” And, somehow, that sentence makes perfect sense in 2025.
The Trip That Wasn’t
Mindstate’s flagship compound, MSD-001, is based on a psychedelic called 5-MeO-MiPT, affectionately known on the street as “moxy.” It’s a member of the same molecular family that gave the world DMT and psilocybin — except Mindstate’s version is AI-bred, algorithmically smoothed, and clinically stripped of its hallucinatory chaos.
In their Dutch trials, 47 volunteers took the drug. They reported heightened emotions, sharper colours, and expanded imagination — but no melting walls, no godly revelations, no “becoming one with the universe.” In short: vibes, not visions.
The AI that designed MSD-001 learned its tricks by devouring 70,000 trip reports scraped from every corner of the human psyche — from clinical trial notes to the dark web’s psychonaut confessionals. The goal wasn’t transcendence. It was pattern recognition. Find out what molecules make people cry, laugh, or dissolve into eternity — then delete the bits that get too weird.
CEO Dillan DiNardo describes the result with a kind of corporate poetry: “It’s quite psychoactive, but there are no hallucinations.” He might as well have said, “It’s a dream you can expense.”
Enter the Psychedelic Tofu
What Mindstate has created, by their own admission, is “psychedelic tofu” — bland on its own, but designed to soak up other flavours. They imagine future drugs built from this base that can induce precise states of consciousness: anxiety reduction, increased insight, enhanced aesthetic appreciation.
In other words, a playlist of mental states, available by prescription.
The company’s AI brain doesn’t dream of electric sheep; it dreams of serotonin receptors. It maps the brain’s 2A receptor — the molecular lock that psychedelics famously pick — then engineers compounds that tickle it just enough to boost neuroplasticity (the brain’s ability to rewire and regenerate), without summoning the ghostly parades of the unconscious mind.
Where old-school psychedelics break open the mind like a cathedral door, MSD-001 simply installs a skylight.
The End of the Vision Quest?
Traditionalists in the psychedelic world are unimpressed. To them, the trip is the medicine — the unpredictable voyage through inner chaos that reveals meaning, grief, or god. Remove the hallucination, they argue, and you’re just microdosing the magic out of existence.
As Rachel Yehuda, director of the Parsons Center for Psychedelic Healing, told Wired: “There are lots of drugs that are mood-altering but not psychedelic. Psychedelics are valuable because of their richness, their unpredictability.” Translation: if you’re not talking to your dead grandmother or merging with a mushroom deity, are you really healing — or just mood-stabilising?
Mindstate’s defence is pragmatic, even humane: many patients can’t risk a full psychedelic trip. Hallucinations are contraindicated for people with psychosis, personality disorders, or severe trauma. For them, a “hallucination-free psychedelic” could be a lifeline — a doorway to healing that doesn’t require losing touch with reality.
Still, the philosophical question lingers: can enlightenment be sanitised for clinical use? Or, in stripping out the madness, do we also delete the meaning?
The FDA and the Digital Shaman
Mindstate’s timing is clever. The FDA recently rejected MDMA-assisted therapy for PTSD, citing inconsistent therapy protocols. That decision sent a chill through the psychedelic industry — and a signal: ditch the therapy, keep the molecule. Mindstate, and others like it, now aim to present psychedelics as standalone drugs, detached from the messy human guidance that traditionally anchors them.
DiNardo envisions MSD-001 being dispensed like Spravato, a ketamine-based antidepressant. Patients take it in a clinic under supervision, but without the candle-lit therapist whispering Jungian affirmations. Just you, your brainwaves, and a quietly humming algorithm that’s already taken the trip on your behalf.
It’s a future in which the shaman is an app, and the sacred set and setting are replaced by clinical lighting and noise-cancelling headphones.
The Algorithmic Psyche
There’s something deeply uncanny about using AI — a technology born from logic and code — to reinvent substances that have always been about chaos and feeling. Psychedelics are, by nature, wildcards: irrational, poetic, humbling. To algorithmically domesticate them feels like teaching a thunderstorm to respect the speed limit.
And yet, perhaps this is inevitable. Psychedelics were always going to be swallowed by capitalism — turned from a countercultural sacrament into a biotech asset. The trip itself may soon be seen as a bug, not a feature.
Mindstate’s investors — who include the founders of OpenAI, Neuralink, Instacart, Coinbase, and Twitch — are betting big that consciousness can be coded, that transcendence can be productised. In a way, it’s the logical endpoint of the Silicon Valley dream: control the chaos, monetise the mystic, regulate the revelation.
From LSD to API
If LSD was about “turning on, tuning in, and dropping out,” Mindstate’s project is about logging in. It’s a new kind of utopia — one where your neurochemistry is optimised, your insight upgraded, your imagination enhanced on a lunch break. No ancient ceremonies. No dangerous introspection. Just the efficient elegance of emotional software.
But here’s the rub: what happens when you can edit your consciousness like a Google Doc? When sadness, awe, and transcendence become settings rather than experiences? At what point does mental health turn into mood curation — a Spotify for the soul?
The danger isn’t that Mindstate’s AI will make bad drugs. It’s that it might make good ones — too good. Smooth, predictable, perfectly calibrated. The kind of psychedelics that never ask you to face yourself.
In the end, Mindstate may have built the first drug to give you insight without intimacy, imagination without ego death, light without shadow. A psychedelic for people who hate surprises.
The least psychedelic psychedelic, indeed — which may be exactly what our anxious, over-optimised era deserves.